http://orcid.org/0000-0002-7518-476X
Figures
Abstract
The genus Onchocerca encompasses parasitic nematodes including Onchocerca volvulus, causative agent of river blindness in humans, and the zoonotic Onchocerca lupi infecting dogs and cats. In dogs, O. lupi adult worms cause ocular lesions of various degrees while humans may bear the brunt of zoonotic onchocercosis with patients requiring neurosurgical intervention because of central nervous system localization of nematodes. Though the zoonotic potential of O. lupi has been well recognized from human cases in Europe, the United States and the Middle East, a proper therapy for curing this parasitic infection in dogs is lacking. To evaluate the efficacy of oxfendazole, 11 out of the 21 client-owned dogs (21/123; 17.1%) positive for skin-dwelling O. lupi microfilariae (mfs), were enrolled in the efficacy study and were treated with oxfendazole (50 mg/kg) per OS once a day for 5 (G2) or 10 (G3) consecutive days or were left untreated (G1). The efficacy of oxfendazole in the reduction of O. lupi mfs was evaluated by microfilarial count and by assessing the percentage of mfs reduction and mean microfilaricidal efficacy, whereas the efficacy in the reduction of ocular lesions was evaluated by ultrasound imaging. All dogs where subjected to follow-ups at 30 (D30), 90 (D90) and 180 (D180) days post-treatment. The percentage of reduction of mfs was 78% for G2 and 12.5% for G3 at D180. The mean microfilaricidal efficacy of oxfendazole in the treatment of canine onchocercosis by O. lupi at D30, D90 and D180 was 41%, 81% and 90%, in G2 and 40%, 65% and 70%, in G3, respectively. Retrobulbar lesions did not reduce from D0 to D180 in control group (dogs in G1), whereas all treated dogs (in G2 and G3) had slightly decreased ocular lesions. Percentage of reduction of ocular lesions by ultrasound examination was 50% and 47.5% in G2 and G3 at D180, respectively. Despite the decrease in ocular lesions in all treated dogs (G2 and G3), oxfendazole was ineffective in reducing ocular lesions and skin-dwelling O. lupi mfs in treated dogs (G2 and G3) in a six-month follow-up period. Here we discuss the need for more reliable diagnostic techniques and efficient treatment protocols to better plan future intervention strategies.
Author summary
The genus Onchocerca (Spirurida, Onchocercidae) includes Onchocerca volvulus, which is estimated to infect at least 37 million people globally, and zoonotic Onchocerca lupi in carnivores. Infection by O. lupi has been reported in dogs and cats from several European countries and recently also in the U.S. and Canada, causing mainly ocular lesions. In humans, O. lupi displays a marked neurotropism with nematodes embedded in nodules localized in the cervical spine of infant, children and adults. Though the reported severity of infection in humans and the high prevalence detected in dogs are now well-recognized, a proper treatment regime for curing this parasitic infection is lacking, being the surgical removal of the parasitic nodule the therapy of choice in canine patients. Hence, there is an unmet medical need for treatment of this zoonotic disease in both humans and animals. In this study we evaluated the efficacy of oxfendazole under two treatment regimes in the reduction of ocular lesions and skin-dwelling microfilariae of O. lupi in naturally infected dogs.
Citation: Colella V, Maia C, Pereira A, Gonçalves N, Caruso M, Martin C, et al. (2018) Evaluation of oxfendazole in the treatment of zoonotic Onchocerca lupi infection in dogs. PLoS Negl Trop Dis 12(1): e0006218. https://doi.org/10.1371/journal.pntd.0006218
Editor: Timothy G. Geary, McGill University, CANADA
Received: October 18, 2017; Accepted: January 6, 2018; Published: January 29, 2018
Copyright: © 2018 Colella et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: DO received a funding from a non-profit organization, namely, Drugs for Neglected disease initiative (DNDi) https://www.dndi.org. IS is currently working at DNDi and contributed with study design and data analysis.
Competing interests: The authors have declared that no competing interests exist.
Introduction
The genus Onchocerca (Spirurida, Onchocercidae) encompasses parasitic nematodes mainly associated to ungulates, with the exception of Onchocerca volvulus in humans and Onchocerca lupi in carnivores [1–3]. While O. volvulus is a well-known parasite estimated to infect 37 million people globally (www.cdc.gov/globalhealth/ntd/diseases/oncho_burden.html), infection by O. lupi has been reported from dogs and cats in Hungary, Greece, Germany, Portugal, Romania and Spain [4–11], and also in the U.S. and Canada [12–18]. Adult O. lupi are found within nodules embedded in ocular tissues and annexes [5, 15, 17], and such presentation commonly leads to clinical diagnosis. However, infections may be associated with no clinical signs [19], to severe ocular disease, including blindness [20]. Nonetheless, the limited number of case reports hinders a thorough understanding of the pathogenesis of canine onchocercosis, including cases with O. lupi in the retrobulbar space of the eye, with no overt sign of infection [15]. In the latter case, imaging techniques (i.e. ultrasound scans and computed tomography [21]), or the detection of microfilariae (mfs) in skin snips [14] are the only diagnostic tools available. For instance, an overall prevalence of infection by O. lupi of 8.4% was recorded by mfs counts in skin biopsy sediments in apparently healthy dogs from Greece and Portugal [19].
Humans may bear the brunt of zoonotic onchocercosis by O. lupi with patients requiring neurosurgical intervention because of nematode localization in the cervical spine of an infant [22] and children [16, 23], thus making central the development of treatment strategies of reservoir animals. However, though the zoonotic potential of O. lupi has been well recognized from cases reported in Europe, the United States and Middle East [15, 16, 24], scientific knowledge on the biology, pathogenesis and treatment of this parasitosis is minimal. A proper treatment regimen for curing this parasitic infection is lacking and the surgical removal of the parasitic nodule has been the therapy of choice in canine patients.
Drug-based treatments included various combination and dosages of melarsomine, ivermectin, topical and systemic antibiotics and prednisone [15, 17, 25]. However, proper studies on the long-term outcomes of these therapies have not yet been performed, and there is an urgent need for studies assessing the efficacy of molecules during natural infection with O. lupi in dogs.
Benzimidazole (BDZ) drugs have a broad-spectrum activity and low toxicity, and have been approved, more than 30 years ago, in human and veterinary medicine against several helminth species, including gastrointestinal parasites and lungworm infections in animals. In this class of drugs, oxibendazole and oxfendazole (OXF) have been increasingly tested as anthelmintics used in human medicine, for their potential efficacy also against tissue-dwelling larval helminths [26, 27].
In addition, benzimidazole drugs (flubendazole, mebendazole, OXF, albendazole, fenbendazole) have shown an in vivo macrofilaricidal activity against several filarial species in animal models [27]. In particular, their efficacy was assessed against larval and adult forms of Brugia malayi, Brugia pahangi, Acanthocheilonema viteae and, Litomosoides sigmodontis, in experimentally infected rodents [28–32]. Significant effects on the microfilaremia after treatment are not always correlated with adulticidal efficacy suggesting that subdoses may alter embryogenesis. However, differences in efficacy of benzimidazoles have been related to the parasite species and the route of drug administration. By subcutaneous administration, OXF has shown either no activity [33] or full protection against adults of B. pahangi [34] whereas it exhibited a marked macrofilaricidal activity against L. sigmodontis [33].
In this study we evaluated the efficacy of OXF under two treatment regimens in the reduction of ocular lesions and skin-dwelling mfs of O. lupi in naturally infected dogs.
Methods
Ethics statement
This study was performed as a negative controlled, blinded and randomised field study in privately owned dogs conducted according to the principles of Good Clinical Practices (VICH GL9 GCP) [35]. The protocol of this study was approved by the Ethical Committee of the Department of Veterinary Medicine of the University of Bari (Prot. Uniba 1/16). All dogs were living in an O. lupi endemic area of Algarve region (southern Portugal [19]), and the study procedures on animals were performed after receiving the owner’s informed consent.
In October 2016, privately owned dogs (n = 123) were sampled via skin snip and positive animals were subjected to ultrasound examination for diagnosing O. lupi infection. All animals lived in the municipalities of Tavira, Faro and Castro Marim.
Skin sampling
Skin samples were collected in the afternoon-evening by using a disposable punch over an area of ≈0.4 × 0.5 cm from the interscapular regions of the dogs [19]. Skin biopsies (one per dog at each time point) were soaked in saline solution for 12 h at room temperature and sediments (20 μL) were individually observed under light microscopy. Microfilariae were identified according to morphological keys [19], and their numbers were assessed from each positive animal by a blinded double-check counting of two independent operators.
Molecular identification
Microfilariae were isolated and genomic DNA extracted using a commercial kit (DNeasy Blood & Tissue Kit, Qiagen, Germany) in accordance with the manufacturer’s instructions. Samples were molecularly processed for specific amplification and sequencing of the partial cytochrome oxidase subunit 1 (cox1) gene (~689 bp), following procedures described elsewhere [36]. Amplicons obtained from the skin sediments were purified using Ultrafree-DA columns (Amicon, Millipore, USA) and sequenced directly with the Taq DyeDeoxyTerminator Cycle Sequencing Kit (v.2, Applied Biosystems, USA) in an automated sequencer (ABI-PRISM 377, Applied Biosystems).
Sequences were aligned using the Geneious R9 software package (http://www.geneious.com) and compared (BLASTn) with those available in the GeneBank database (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Ultrasound examination
Following the assessment of mfs counts, each positive animal was checked by an ultrasound examination of both eyes and retrobulbar spaces as follow. Briefly, 1–2 minutes prior to the exam oxibuprocain chloridrate (Anestocil, Laboratório Edol, Portugal) was used as local anaesthetic, placing a few drops on each eye, with animals restrained in sternal recumbence. The eye and the retrobulbar space were scanned with a portable ultrasound Logic Book–GE, equipped with two probes, one linear and one microconvex, with frequency ranges from 6–10 MHz, through transcorneal, transscleral and transpalpebral approaches, along horizontal, vertical and oblique planes to check for lesions associated with the presence of adult parasites.
Enrolment and follow up
Naturally infected dogs were enrolled in the study if scored positive for O. lupi mfs at skin sediment observation and further molecular diagnostic confirmation. Nodules or hyper-echogenic lesions caused by adult nematodes were also assessed. Dogs were allocated to study groups in blocks following a random treatment allocation plan on the basis of an inclusion sequence. Each dog, per block, was randomly assigned to one untreated control group (G1) and to treated groups (G2 and G3). Animals were treated with Dolthene (Boheringer Ingelheim, Germany) a commercial oral suspension of OXF for dogs containing 22.65 mg/ml of OXF, 1.5mg/ml of sorbic acid (E200), macrogol, macrogol stearate, sodium carboxymethyl cellulose, silica colloidal anhydrous, citric acid monohydrate (E330), sodium citrate and purified water. A dose of 50 mg/kg per body weight per OS once daily for 5 (G2) or 10 (G3) consecutive days was administrated. No information is available on the in vitro activity of OXF against O. lupi microfilaria or adult parasites. Furthermore in vitro activity of anthelmintic benzimidazoles in general is difficult to be assessed [37, 38]. Therefore, a relevant drug concentration to be achieved in plasma of infected animals cannot derive from in vitro efficacy studies. To maximise the chance of observing a pharmacological effect a high dose of 50mg/kg/day for 5 (G2) and 10 (G3) consecutive days was selected to achieve a plasma disposition of OXF during the whole treatment duration above approximately 1 μg/ml [39]. Efficacy of the treatment was assessed by microfilarial count and presence and size of ocular nodules, at 30 (D30), 90 (D90) and 180 (D180) days post-treatment.
Assessment of the efficacy and statistical analyses
The percentage (%) of reduction [s] of ocular lesions was calculated as follow [s] = [(Cs0 –Cs) / Cs0] x 100, where Cs0 is the baseline ocular size lesion before treatment and Cs was the count at Cs was the count at any time point (s). The percentage (%) of reduction [t] of mfs was calculated as follow [t] = [(Ct0 –Ct) / Ct0] x 100, where Ct0 is the baseline count before treatment and Ct was the count at any time point (t). Moreover, mean microfilaricidal efficacy (%) = [(Ct–T) / Ct] x 100, where Ct is the mean count of mfs of the control group at X time and T is the mean count of mfs of the treated animal groups at X time. The significance of the mfs count reduction and mean microfilaricidal efficacy in treated dogs was analysed by ANOVA, with standard statistical assumption. Statistical analysis was planned and conducted in compliance with current guidelines [40]. Statistical calculations and randomization were performed with SPSS statistical package for Windows, version 13.0, and nQuery+nTerim 3.0 (StatSols), Statistical Solutions Ltd. 2014, Microsoft. A post-hoc power calculation on the mfs counts and ocular lesions at day 0 and at the several days of measurement has been calculated by the software GPower 3.1.9.2, using the module F-test, ANOVA model for repeated measures with between-within factor interaction, setting the power at 80% and significance level at 0.05 and the sample size was evaluated in function of effect size.
Pharmacokinetic of oxfendazole
In order to assess the pharmacokinetic of OXF, and the metabolites fenbendazole (FBZ) and fenbendazole-sulfone (FBZSO2), heparinised blood samples were collected by cephalic vein puncture prior to the start of treatment from all dogs (G1, G2 and G3 groups) and, once a day, at different time points (i.e., +1, +5, +6, +7 day post treatment (pt) for G2, and +1, +5, +10, +11 and +12 day pt for G3). Samples were collected immediately prior to the daily drug administration.
A 20 μL samples of whole blood sample from each animal was transferred into 96-well polypropylene plate and added with 20 μL of blank dog plasma. After mixing a volume of 400 μL of acetonitrile was added to each well. The plate was than mixed and centrifuged at 2100 g for 20 min and 2 μL of supernatant was directly injected in the LC-MS/MS system. Calibration standards in the range of 1 to 5000 ng/mL and added with 20 μL of blank dog whole blood were included in duplicate at each run.
OXF, FBZ and FBZSO2 were detected and quantified using an Agilent 1100 series HPLC connected to a API4000 QTRAP Mass Spectrophotometer (SCIEX, Applied Biosystems, USA). Chromatographic separation was achieved using a Kinetex C18 analytical column (50*3.0mm, 2.6 mm. Phenomenex, USA) column maintained at 40°C and eluted with a gradient of ammonium acetate (10 mM) and acetonitrile. The run time was 0.6 min. The detection and quantification of the three compounds was performed in the tandem mass spectrometry operated in positive electro-spray ionisation and multiple reaction monitoring mode using the transition range of m/z 316–191.2 for OXF, 300.1–268.2 for FBZ and 332.1–300.3 for FBZSO2. The ion source and gas parameters were: curtain gas 20 psi, ion source gas 45 (GS1) and 40 (GS2), source temperature 450°C and collision gas set to medium. The optimized acquisition parameters for the three analytes were: declustering potential 95 V for OXF and FBZSO2 and 120 V for FBZ); entrance potential 10 V for all analytes; collision energy 30 V, 28 V and 31 V for OXF, FBZ and FBZSO2, respectively and collision cell exit potential 15 V for OXF and f FBZSO2 and 10 V for FBZ.
The performance of the LC-MS/ MS method was tested using a short validation protocol. Linearity of calibration was confirmed at concentrations ranging from 2.5 to 5000 ng/mL (r2 = 0.9975) for OXF, from 1.0 to 1000 ng/mL (r2 = 0.9964) for FBZ and from 1.0 to 2500 ng/mL (r2 = 0.995) for FBZSO2. The mean extraction recovery was not less than 80% for all analytes tested and the accuracy (expressed as %Bias) and precision (expressed as % CV) of the method ranged from -2.9 to 3.4% and 2.5 to 6.7% respectively for OXF, from -1.6 to 2.0% and 2.8 to 6.4% for FBZ and from -10.4 to 6.4%, and 0.1 to 9.0% for FBZSO2. The lower limit of quantification (LLOQ) was 2.5 ng/mL for OXF and 1.0 ng/mL for FBZ and FBZSO2. Results were expressed as mean (± s.e.m.). Differences in drug blood concentration at different sampling times were determined using one-way ANOVA and results were considered statistically significant when p<0.05.
Results
Of the 123 animal sampled, 21 (17.1%) scored positive for O. lupi mfs, out of which 11 were enrolled in the efficacy study and assigned to groups G1 (dogs 1–4), G2 (dogs 5–8) and G3 (dogs 9–11). The mean number of O. lupi microfilariae in skin sediment was homogenous amongst the three groups (p<0.05). The morphological identification of mfs was molecularly confirmed, and nucleotide sequences obtained from mfs DNA (GenBank; accession number: MG677940) displayed 100% identity with those of O. lupi from Portugal (GenBank; accession number: EF521410).
Efficacy study
The count number of O. lupi mfs at each study day is reported in Table 1. The percentage of reduction of mfs was 78% for G2 and 12.5% for G3 at D180. Mean microfilaricidal efficacy of OXF in the treatment of canine onchocercosis by O. lupi was 41%, 81% and 90%, respectively at D30, D90 and D180 in G2 compared to G1 and 40%, 65% and 70%, respectively at D30, D90 and D180 in G3 compared to G1. Differences in mean microfilaricidal efficacy in animals in G2 and G3 compared to the control group (G1) were not statistically significant at all time points, except at D90 between G2 and control group (p<0.05).
On D0, eight dogs (i.e. nos. 1, 4, 5, 6, 7, 9, 10, 11) had hyper-echogenic lesions (0.7–2.5 mm wide) in the retrobulbar space overlapping the localization and the dimensions of O. lupi adult nematodes. At the ultrasound examination, retrobulbar lesions did not reduce from D0 to D180 in dogs of the G1, whereas one dog of G2 (no. 7) cleared the ocular lesion and all the other dogs of treatment groups had a slightly decreased size of ocular lesions (Figs 1 and 2). Percentage of reduction of ocular lesions by ultrasound examination was not statistically significant, being of 50% and 47.5% at D180 in G2 and G3, respectively.
Size of ocular lesions detected at the ultrasound imaging of eyes of dogs at 0 (D0), 30 (D30), 90 (D90) and 180 (D180) days post enrolment in animals in G1 (1–4), G2 (5–8) and G3 (8–11). RE = Right Eye; LE = Left Eye.
Decreased ocular size lesions in dogs n. 5 (A) and n. 9 (B) at 0 (D0), 90 (D90) and 180 (D180) days post enrolment.
Pharmacokinetic results
All samples collected from untreated dogs were below the limit of detection of the method. The plasma concentrations time curves of OXF and its metabolites following oral administration of 50 mg/kg for 5 or 10 days are shown in Figs 3 and 4. At the zero-time point, prior to the first administration, the mean of OXF plasma levels is above zero, this likely caused by a carryover effect. Standard deviations of measured plasma levels indicate high variability from day 1 to day 5 and day 10, while OXF is administrated to animals. Among others, the heterogeneity of treated animals, in regards of species, weight and age is likely to be the cause for such variability. Over the 5-days period blood mean concentration of OXF varied at trough level 0.49±0.24 μg/mL on day 1 to 0.98±0.74 μg/mL on day 5 and over the 10-days period from 0.23±0.13 μg/mL on day 1 to 0.78±0.17 μg/mL on day 5. By 1 day after the last dosing (day 6 and day 11, respectively) the drug blood concentrations were maintained at similar levels than those recorded during the treatment and they fell to 0.005±0.002 μg/mL and 0.003±0.001 μg/mL 2 days after the last drug administration (day 7 and day 12 respectively). No significant differences among the blood drug concentrations were recorded from the first day treatment to the first day post-treatment (one-way ANOVA). In conclusion, the overall exposure of OXF was sustained in all animals during the whole treatment duration. In both administration protocols, the blood concentration of FBZSO2 followed a similar but lower pattern to OXF. Over the 5-days period, the mean concentration percentage of FBZSO2 compare to OXF varied from 27% on day 1 to 34% on day 6; over the 10-days period, a similar variation is observed: 31% on day 1, to 17% on day 5 and to 31% on day 11. The metabolic biotrasformation of the parent drugs into the reduced metabolites fenbendazole was negligible.
Mean (± s.e.m.) blood concentrations (μg/mL) of oxfendazole (square) and its metabolites fenbendazole (triangle) and fenbendazole-sulfone (triangle) following oral administration of 50 mg/kg b.w. for 5 days in dogs (n = 4).
Mean (± s.e.m.) blood concentrations (μg/mL) of oxfendazole (square) and its metabolites fenbendazole (triangle) and fenbendazole-sulfone (triangle) following oral administration of 50 mg/kg b.w. for 10 days in dogs (n = 3).
Discussion
In this study, OXF was ineffective in reducing ocular lesions and skin-dwelling mfs of O. lupi in naturally infected dogs in a six-month follow-up period. Though one treated dog cleared the ocular lesions, OXF did not show any major efficacy in reducing the size of hyper-echogenic areas in the retrobulbar space. Ultrasound examination has several limitations in the detection of the parasites, including lack of sensitivity and specificity, but represents the only option available to detect nematodes with retrobulbar localization [21].
Only at D90, but not D180, OXF showed a significant efficacy in reducing the number of mfs in animals from G2 compared to the control group. Moreover, the increased number of mfs in 6 out of 11 dogs from D30 to D180 together with the lack of significant decrease of size of ocular lesions stands for a lack of efficacy in treatment of canine onchocercosis. In addition, this variation in number of mfs from November (D30) to April (D180) may indicate the existence of a seasonal pattern, which may match with the behaviour of the as-yet-unknown vector species. Up to now, the detection of DNA in wild-caught Simulium tribulatum indicates this simulid species as putative vector in California [41], though further studies are needed to ascertain species of vectors involved in the epidemiology of O. lupi. The seasonal variation in O. lupi mfs would add further information to their circadian rhythm [42], also considering that seasonal pattern has been well studied in the life-cycles of O. volvulus and Dirofilaria immitis [43–46].
The highest percentage of reduction of mfs in dogs treated for 5 days rather than for 10 days (78% vs 12.5%) is unexpected. OXF is a macrofilaricide and the evaluation of its efficacy solely based on mfs counting may be troublesome, also considering that their lifespan in the definitive hosts is unknown. Moreover, the enrolment of naturally infected animals in this trial was challenging and resulted in a limited number of dogs included in the study. Indeed, it would have been desirable a large effect size (large difference between first observations and subsequent follow-ups) like the one observed, albeit variances of the model resulted very small to achieve 80% power, i.e. a higher level of probability that there is an effect if the differences are statistically significant, a greater sample size should be recruited, with a lower effect size that is still clinically interesting.
Nevertheless, benzimidazoles, including OXF, have been described, as tubulin inhibitors, preventing polymerisation of the tubulin subunit α and ß [47]. Though this mechanism of action is compatible with inhibition of the embryogenesis [48, 49], this effect did not seem to occur in the present study. Further explanations for the lack of efficacy of OXF may be the pharmacokinetic differences, though not statistically significant, in dogs from G2 and G3 (mean blood concentration 0.49–0.97 in G2 vs 0.23–0.78 μg/mL in G3). The concentration of OXF, FBZSO2 and FBZ, measured at the trough level is in the same range of previous assessment of the plasma disposition in dogs at the same dosage (i.e. 50mg/kg) after a single administration [39]. The metabolic biotransformation of OXF occurs via oxidation of the sulfoxide group of OXF to form FBZSO2. This is consistent with oral pharmacokinetic studies conducted in cattle, sheep, dog and pig, where such pattern was observed as well over a period of 24 hours [50]. However, this is not case in horses and rats where plasma concentration of OXF is less abundant compared to FBZ and FBZSO2 respectively, over a period of 24 hours [50]. In sheep, an equilibrium between FBZ and OXF has been described in vivo [51]. This was not observed in the current study (Figs 3 and 4) where formation of FBZ is negligible as reported by [39]. Following 5 and 10 consecutive days of drug administration, OXF blood concentration did not vary being almost undetectable after the second day from the last administration (i.e. at day 7 and day 12 in G2 and G3, respectively). This data may be beneficial for future efficacy studies and confirm the shorter blood retention time of OXF in dogs’ plasma (see also [39]).
Despite a sustained exposure of OXF was observed in all dogs in treatment group, the drug concentration in the nodules is unknown. Also, vascularization of O. lupi nodules is not described and it is possible that OXF plasma concentration is not representative of the drug concentration that will eventually reach the adult parasites. Although OXF is a broad spectrum anthelmintic effective for several filarial species [52], it may be not effective against O. lupi.
The percentage of dogs positive (17.1%) for O. lupi mfs represents the highest prevalence of canine onchocercosis detected, as in an epidemiological study performed in dogs from Algarve the 8.3% of the examined animals scored positive [19]. Remarkably, animals in the abovementioned survey and those in the present study were clinically healthy, drawing the attention on the role of dogs as suitable reservoir of O. lupi in endemic area.
The absence of palpable nodules together with the lack of ocular lesions at ultrasound examination in some of the study animals, which harboured mfs in their skins, imply the potential presence of adult nematodes in other anatomical localization. For instance, gravid females of O. lupi were found in the thyroid cartilage of a dog in Portugal, with no involvement of ocular tissues [53]. Additionally, in a retrospective study of cases from dogs in New Mexico (U.S.), the 67% of animals treated with melarsomine, ivermectin and doxycycline had recurrent ocular disease [17], which was in contrast with a similar study in Greece, where no recurrence was noticed after drug administration [5]. This apparent challenge in treating animals from the U.S. has been attributed to the presence of a single haplotype circulating in this country [17]. Again, humans infected by O. lupi from the U.S. displayed more severe diseases (e.g. spinal and orbital localization) but not subconjunctival nodules [16]. A recent phylogenetic analysis indicates that Onchocerca species form a monophyletic group encompassing three clades, one of which composed of Onchocerca gutturosa, O. linealis and Onchocerca ochengi of domestic bovids, O. volvulus of humans and O. lupi [3]. In addition O. ochengi and O. volvulus are sister species, with O. lupi being basal to this clade [3]. In that study based on a single-gene analysis O. lupi showed a large genetic intraspecific variability, suggesting the existence of two clades, one detected only from Portugal and all the others distributed in Europe and in the U.S. and this is consistent with either two- or seven-gene analysis [3, 13]. Nonetheless, epidemiological and clinical studies coupled with the genetic traits of O. lupi should be conducted to elucidate whether haplotypes occurring in different geographical areas could play a role in the disease ecology and treatment efficacy.
Non-surgical treatment strategies may include the use of microfilaricide and anti-symbiont drugs. For instance, among available pharmaceutical options ivermectin showed to be effective against O. volvulus mfs [54, 55].
With the exception of Onchocerca flexuosa, Wolbachia symbionts have been detected in all the species of the Onchocerca genus [56], including O. lupi [12, 57] making this species a potential focus for symbiont-targeted therapy. Among others, these bacteria favour the survival of the mfs and interact with the cell of the immune system modulating responses to inflammation. Hence, treatments aiming at Wolbachia results in sterilization and death of the adult worms and first-to-third larval moulting blockage [58]. Nonetheless, though the clade in which O. lupi clusters have the strongest co-evolutionary pattern with their Wolbachia symbionts [3], few studies included anti-Wolbachia treatments as potential target for therapy [17].
Undoubtedly, a defined treatment protocol for this infection is still lacking and the therapies employed up to now mostly derive from clinical experience on the treatment of heartworm disease in dogs [59, 60]. Infections with O. lupi can inflict important hardship on the health of people, and there is an unmet medical need for treatment of this zoonotic disease in both humans and animals. Future efficacy studies are, therefore, urgently needed and should take into account the difficulties in the detection of adult and larval stages of this zoonotic filarioid.
Acknowledgments
Authors are thankful to the dog owners and to the administrators of Federação de Caçadores do Algarve, Clube de Caçadores e Pescadores de Tavira and to Dr. Paolo Trerotoli (University of Bari) for the assistance with the statistical analysis.
References
- 1.
Bain O. Evolutionary relationships among filarial nematodes. In: Klei T.R., Rajan T.V. (Eds.), The Filaria. Kluwer Academic Publishers, Boston, USA, 2002;21–29.
- 2.
Bain O, Mutafchiev Y, Junker K. Order Spirurida. In: Schmidt-Rhaesa A. (Ed.), Handbook of Zoology, Vol. 2. Nematoda. De Gruyter, Berlin, Germany, 2013;661–732.
- 3. Lefoulon E, Giannelli A, Makepeace BL, Mutafchiev Y, Townson S, Uni S, et al. Whence river blindness? The domestication of mammals and host-parasite co-evolution in the nematode genus Onchocerca. Int J Parasitol. 2017;47(8):457–470. pmid:28344097
- 4. Szell Z, Erdelyi I, Sreter T, Albert M, Varga I. Canine ocular onchocercosis in Hungary. Vet Parasitol 2001;97:243–249. pmid:11390077
- 5. Komnenou A, Eberhard ML, Kaldrymidou E, Tsalie E, Dessiris A. Subconjunctival filariasis due to Onchocerca sp. in dogs: report of 23 cases in Greece. Vet Ophthalmol 2002;5:119–126. pmid:12071870
- 6. Hermosilla C, Hetzel U, Bausch M, Grübl J, Bauer C. First autochthonous case of canine ocular onchocercosis in Germany. Vet Rec 2005;156:450–452. pmid:15828728
- 7. Faísca P, Morales-Hojas R, Alves M, Gomes J, Botelho M, Melo M, et al. A case of canine ocular onchocercosis in Portugal. Vet Ophthalmol 2010; 13:117–121. pmid:20447031
- 8. Maia C, Annoscia G, Latrofa MS, Pereira A, Giannelli A, Pedroso L, et al. Onchocerca lupi nematode in cat, Portugal. Emerg Infect Dis. 2015;21:2252–2253. pmid:26584050
- 9. Tudor P, Turcitu M, Mateescu C, Dantas-Torres F, Tudor N, Bărbuceanu F, et al. Zoonotic ocular onchocercosis caused by Onchocerca lupi in dogs in Romania. Parasitol Res. 2016;115(2):859–62. pmid:26561013
- 10. Hodžić A, Hinney B, König S, Naucke TJ, Duscher G, Joachim A. A case of ocular infection with Onchocerca lupi in a dog from Germany. Transbound Emerg Dis. 2017;17. pmid:28921893
- 11. Miró G, Montoya A, Checa R, Gálvez R, Mínguez JJ, Marino V, et al. First detection of Onchocerca lupi infection in dogs in southern Spain. Parasit Vectors. 2016;9(1):290. pmid:27193758
- 12. Labelle AL, Daniels JB, Dix M, Labelle P. Onchocerca lupi causing ocular disease in two cats. Vet Ophthalmol 2011;14:105–110. pmid:21923832
- 13. Labelle AL, Maddox CW, Daniels JB, Lanka S, Eggett TE, Dubielzig RR, et al. Canine ocular onchocercosis in the United States is associated with Onchocerca lupi. Vet Parasitol 2013;193: 297–301. pmid:23276598
- 14. Otranto D, Giannelli A, Latrofa MS, Dantas-Torres F, Trumble NS, Chavkin M, et al. Canine Infections with Onchocerca lupi Nematodes, United States, 2011–2014. Emerg Infect Dis. 2015;(5):868–71. pmid:25897859
- 15. Otranto D, Giannelli A, Trumble SN, Chavkin M, Kennard G, Latrofa MS, et al. Clinical case presentation and a review of the literature of canine onchocercosis by Onchocerca lupi in the United States. Parasit Vectors 2015;8:89. pmid:25884672
- 16. Cantey PT, Eberhard M, Weeks J, Swoboda S, Ostovar GA. Letter to the Editor: Onchocerca lupi infection. J Neurosurg Pediatr. 2016;17(1):118–119. pmid:26451719
- 17. McLean NJ, Newkirk K, Adema CM. Canine ocular onchocerciasis: a retrospective review of the diagnosis, treatment, and outcome of 16 cases in New Mexico (2011–2015). Vet Ophthalmol. 2017;20(4):349–356. pmid:27624855
- 18. Verocai GG, Conboy G, Lejeune M, Marron F, Hanna P, MacDonald E, et al. Onchocerca lupi nematodes in dogs exported from the United States into Canada. Emerg Infect Dis 2016;22:1477–1479. pmid:27434170
- 19. Otranto D, Dantas-Torres F, Giannelli A, Latrofa MS, Papadopoulos E, Cardoso L, et al. Zoonotic Onchocerca lupi in dogs from Greece and Portugal. Emerg Infect Dis. 2013;19(12):2000–2003. pmid:24274145
- 20. Sreter T, Szell Z. Onchocercosis: a newly recognized disease in dogs. Vet Parasitol 2008;15:1–13.
- 21. Franchini D, Giannelli A, Di Paola G, Cortes H, Cardoso L, Lia RP, et al. Image diagnosis of zoonotic onchocercosis by Onchocerca lupi. Vet Parasitol. 2013; 203:91–95.
- 22. Eberhard ML, Ostovar GA, Chundu K, Hobohm D, Feiz-Erfan I, Mathison BA, et al. Zoonotic Onchocerca lupi infection in a 22-month-old child in Arizona: first report in the United States and a review of the literature. Am J Trop Med Hyg. 2013;88(3):601–605. pmid:23382171
- 23. Dudley RW, Smith C, Dishop M, Mirsky D, Handler MH, Rao S. A cervical spine mass caused by Onchocerca lupi. Lancet 2015;386(10001):1372. pmid:25843892
- 24. Mowlavi G, Farzbod F, Kheirkhah A, Mobedi I, Bowman DD, Naddaf SR. Human ocular onchocerciasis caused by Onchocerca lupi (Spirurida, Onchocercidae) in Iran. J. Helminthol. 2014;88:250–255. pmid:23388686
- 25. Grácio AJ, Richter J, Komnenou AT, Grácio AM. Onchocerciasis caused by Onchocerca lupi: an emerging zoonotic infection. Systematic review. Parasitology Research 2015; 114: 2401–2413. pmid:25990062
- 26. Gavidia CM, Gonzalez AE, Barron EA, Ninaquispe B, Llamosas M, Verastegui MR, et al. Evaluation of oxfendazole, praziquantel and albendazole against cystic echinococcosis: a randomized clinical trial in naturally infected sheep. PLoS Negl Trop Dis. 2010;4:e616. pmid:20186332
- 27. Geary TG, Mackenzie CD. Progress and challenges in the discovery of macrofilaricidal drugs. Expert Rev Anti Infect Ther. 2011;9(8):681–695. pmid:21819332
- 28. Denham DA, Brandt E. Chemoprophylactic activity of flubendazole against adult Brugia pahangi transplanted into the peritoneal cavity of jirds. J Parasitol. 1980;66(6):933–934. pmid:7218115
- 29. Denham DA, Liron DA, Brandt E. The anthelmintic effects of albendazole on Brugia pahangi. J Helminthol. 1980;54(3):199–200. pmid:7217649
- 30. Denham DA, Samad R, Cho SY, Suswillo RR, Skippins SC. The anthelmintic effects of flubendazole on Brugia pahangi. Trans R Soc Trop Med Hyg. 1979;73(6):673–676. pmid:538808
- 31. Devaney E, Howells RE, Smith G. Brugia pahangi in the BALB/C mouse: a model for testing filaricidal compounds. J Helminthol. 1985;59(2):95–99. pmid:3843374
- 32. Zahner H, Schares G. Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi. Acta Trop. 1993;52(4):221–266. pmid:8094587
- 33. Reddy AB, Rao UR, Chandrashekar R, Shrivastava R, Subrahmanyam D. Comparative efficacy of some benzimidazoles and amoscanate (Go.9333) against experimental filarial infections. Tropenmed Parasitol. 1983;34(4):259–262. pmid:6665868
- 34. Surin J, Denham DA. Comparative susceptibility to anthelmintics of Brugia pahangi in jirds infected by different methods. J Helminthol. 1990;64(3):232–238. pmid:2230033
- 35.
VICH GL9 GCP, 2000 Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004343.pdf.
- 36. Otranto D, Dantas-Torres F, Cebeci Z, Yeniad B, Buyukbabani N, Boral OB, et al. Human ocular filariasis: further evidence on the zoonotic role of Onchocerca lupi. Parasit Vectors 2012;5:84. pmid:22541132
- 37. Strote G, Wieland S, Darge K, Comley JC. In vitro assessment of the activity of anthelmintic compounds on adults of Onchocerca volvulus. Acta Leiden. 1990;59(1–2):285–96. pmid:2378212
- 38. Townson S, Connelly C, Dobinson A, Muller R. Drug activity against Onchocerca gutturosa males in vitro: a model for chemotherapeutic research on onchocerciasis. J Helminthol 1987;61:271–281. pmid:3437107
- 39. Gokbulut C, Bilgili A, Hanedan B, McKellar QA. Comparative plasma disposition of fenbendazole, oxfendazole and albendazole in dogs. Vet Parasitol. 2007;148(3–4):279–87. pmid:17673370
- 40.
EMA/CVMP/EWP/81976/2010. Guideline on statistical principles for clinical trials for veterinary medicinal products (pharmaceuticals). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/01/WC500120834.pdf).
- 41. Hassan HK, Bolcen S, Kubofcik J, Nutman TB, Eberhard ML, Middleton K, et al. Isolation of Onchocerca lupi in Dogs and Black Flies, California, USA. Emerg Infect Dis. 2015;21(5):789–96. pmid:25897954
- 42. Otranto D, Dantas-Torres F, Giannelli A, Abramo F, Ignjatović Ćupina A, Petrić D, Cardoso L, Mutafchiev Y, Cortes H. Cutaneous distribution and circadian rhythm of Onchocerca lupi microfilariae in dogs. PLoS Negl Trop Dis. 2013;7(12):e2585. pmid:24349594
- 43. Sasa M, Tanaka H. Studies on the methods for statistical analysis of the microfilarial periodicity survey data. Southeast Asian J. Trop. Med. Publ. Hlth. 1972;4:518–536
- 44. Hawking F. The 24-hour periodicity of microfilariae: biological mechanisms responsible for its production and control. Proc. R. Soc. B. 1967;169:59–67.
- 45. Newton WL. Longevity of an experimental infection with Dirofilaria immitis in a dog. J. Parasitol. 1968;54:187–188. pmid:5641045
- 46. Lovis L, Grandjean M, Overney L, Seewald W, Sager H. Seasonality and circadian variation of microfilaremia in dogs experimentally infected with Dirofilaria immitis. Vet Parasitol. 2017;243:235–241. pmid:28807299
- 47. Lacey E. Mode of action of benzimidazoles. Parasitol Today. 1990;6(4):112–115 pmid:15463312
- 48. O'Neill M, Mansour A, DiCosty U, Geary J, Dzimianski M, McCall SD, et al. An in vitro/in vivo model to analyze the effects of flubendazole exposure on adult female Brugia malayi. PLoS Negl Trop Dis. 2016;10(5):e0004698. pmid:27145083
- 49. Dominguez-Vazquez A, Taylor HR, Greene BM, Ruvalcaba-Macias AM, Rivas-Alcala AR, Murphy RP, et al. Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet 1983;1(8317):139–143. pmid:6130195
- 50.
http://www.fao.org/fileadmin/user_upload/vetdrug/docs/41-4-oxfendazole.pdf. Last accessed 27th December 2017.
- 51. Gottschall DW, Theodorides VJ, Wang R The metabolism of benzimidazole anthelmintics. Parasitol Today. 1990 Apr;6(4):115–24. pmid:15463313
- 52. Zahner H, Schares G. Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi. Acta Trop. 1993;52(4):221–266. pmid:8094587
- 53. Alho AM, Cruz L, Coelho A, Martinho F, Mansinho M, Annoscia G, et al. Aberrant laryngeal location of Onchocerca lupi in a dog. Parasitol Int. 2016;65(3):218–20. pmid:26732654
- 54. Cupp EW, Cupp MS. Short report: impact of ivermectin community-level treatments on elimination of adult Onchocerca volvulus when individuals receive multiple treatments per year. Am J Trop Med Hyg. 2005;73:1159–1161. pmid:16354830
- 55. Basanez MG, Pion SD, Boakes E, Filipe JA, Churcher TS, Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008; 8:310–322. pmid:18471776
- 56. Lefoulon E, Bain O, Makepeace B, d’Haese C, Uni S, Martin C. Gavotte L. Breakdown of coevolution between symbiotic bacteria Wolbachia and their filarial hosts. PeerJ 4 2016;e1840. pmid:27069790
- 57. Egyed Z, Sréter T, Széll Z, Nyiro G, Márialigeti K, Varga I. Molecular phylogenetic analysis of Onchocerca lupi and its Wolbachia endosymbiont. Vet Parasitol. 2002;108(2):153–61. pmid:12208043
- 58. Bouchery T, Lefoulon E, Karadjian G, Nieguitsila A, Martin C. The symbiotic role of Wolbachia in Onchocercidae and its impact on filariasis. Clin Microbiol Infect. 2013;19(2):131–40. pmid:23398406
- 59. Bazzocchi C, Mortarino M, Grandi G, Kramer LH, Genchi C, Bandi C, et al. Combined ivermectin and doxycycline treatment has microfilaricidal and adulticidal activity against Dirofilaria immitis in experimentally infected dogs. Int J Parasitol. 2008;38(12):1401–10. pmid:18433753
- 60. Grandi G, Quintavalla C, Mavropoulou A, Genchi M, Gnudi G, Bertoni G, et al. A combination of doxycycline and ivermectin is adulticidal in dogs with naturally acquired heartworm disease (Dirofilaria immitis). Vet Parasitol. 2010;169(3–4):347–351. pmid:20144506